Turmeric Capital

Bruce Richards, the Founder and CEO, leads investment decisions. He previously served as Senior Managing Director at Highland Capital Management, where he ran Asia-Pacific credit and private equity strategies. Richards brings over two decades of principal investing experience in the region.

Turmeric sources primarily through Richards' multi-decade institutional LP network and direct founder relationships across Singapore, Bengaluru, and Jakarta. The firm's independent sponsor model enables it to move quickly on off-market opportunities without fund-formation timelines.

No. Turmeric operates as an independent sponsor rather than a traditional closed-end fund. This means it raises capital on a deal-by-deal basis, which gives the firm flexibility to hold portfolio companies longer and co-invest alongside sovereign wealth funds and family offices without vintage-year pressure.

The firm deploys across venture and growth equity, typically participating in Series B through pre-IPO rounds. Its focus is on mid-to-late-stage companies that have demonstrated product-market fit and are seeking capital to scale across Southeast Asia and India.

Turmeric has disclosed a focus on technology, healthcare, consumer, and media sectors. Confirmed sub-sectors include enterprise software, fintech infrastructure, and digital health platforms across the ASEAN region and India (per public record, 2023).

Turmeric primarily makes direct equity investments in portfolio companies. There is no public record indicating the firm operates a fund-of-funds program or allocates to third-party GPs.

Headquartered in Singapore, Turmeric invests across Southeast Asia and India. Its deal flow concentrates on Singapore, Indonesia, and India, where Richards' network is deepest, though the firm can pursue opportunities across the broader Asia-Pacific region.